8-KRegulation FD

Cencora, Inc. 8-K Report, Regulation FD Disclosure (Apr 2, 2018)

Filed April 2, 2018For Securities:COR

Summary

Cencora, Inc. (formerly AmerisourceBergen Corporation) filed an 8-K on April 2, 2018, to provide an update on its PharMEDium 503B outsourcing facility in Memphis, Tennessee. Production at this facility has remained voluntarily suspended since December 2017, following FDA inspections. The company is actively engaged with the FDA and is working to complete necessary remedial measures to resume operations as soon as possible. Investors should note that the company expects to provide a further financial update when it reports its fiscal second quarter results on May 8, 2018. While patient safety is emphasized as the top priority, the prolonged suspension of operations at a key facility could impact near-term financial performance. The filing also includes a comprehensive cautionary note regarding forward-looking statements, highlighting various risks that could affect future results.

Key Highlights

  • 1Voluntary suspension of production at PharMEDium's Memphis 503B outsourcing facility continues since December 2017.
  • 2The company is actively working with the FDA to complete remediation measures and resume production.
  • 3A financial update is expected on May 8, 2018, coinciding with the fiscal second quarter earnings release.
  • 4Patient safety and regulatory compliance are stated as the company's top priorities.
  • 5The company acknowledges significant patient need and market demand for compounded sterile preparation products.
  • 6The filing includes extensive forward-looking statements detailing numerous risks and uncertainties that could impact future financial results.

Frequently Asked Questions

Production at PharMEDium's 503B outsourcing facility in Memphis, Tennessee, remains voluntarily suspended as of April 2, 2018. This suspension began in December 2017 following FDA inspections.

Cencora plans to provide a financial update when it releases its fiscal second quarter results before the market opens on Tuesday, May 8, 2018.

The company is in active communication with the FDA and is working to complete necessary remedial measures to resume production at the Memphis facility as soon as possible.

Yes, the filing includes a detailed 'Cautionary Note Regarding Forward-Looking Statements' that outlines numerous factors that could cause actual results to differ materially from expectations. These include regulatory changes, competition, legal proceedings, operational risks, and the successful integration of acquired businesses.